Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma

Yu-Jie Xu(Guangzhou First People's Hospital), QiJiong Li(Sun Yat-sen University), Yaojun Zhang(Sun Yat-sen University), Yuan-Min Zhou(Twelfth Guangzhou City People's Hospital), ZhiCheng Lai(Sun Yat-sen University), Li Xu(Jiangxi University of Traditional Chinese Medicine), Ming Shi(Yanshan University), Wei Wei(Zhujiang Hospital), Xiaoyun Bu(Xiamen Blood Center), Minshan Chen(Sun Yat-sen University), Minke He(Sun Yat-sen University), Huanwei Chen(Changhua Christian Hospital), Rong Guo(Sun Yat-sen University)
Technology in Cancer Research & Treatment
January 1, 2021
10.1177/15330338211063848
Cited by 34

Related Papers

Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417